Results 61 to 70 of about 51,359 (249)

ZBTB11 Promotes Breast Cancer Progression by Activating FBXO28‐Mediated MST1 Degradation and Suppressing Hippo Signaling

Advanced Science, EarlyView.
ZBTB11 is identified as an oncogenic transcription factor that activates FBXO28 in breast cancer. FBXO28 promotes K48‐linked ubiquitination and degradation of MST1, suppressing Hippo signaling and enhancing epithelial–mesenchymal transition and metastasis. This transcription‐to‐ubiquitination cascade defines a prognostic biomarker axis and highlights a
An Xu, Xiang‐Nan Xu, Xiao Huang, Zhou Luo, Chun‐Lian Li, Yang Du, Cheng Yan, Xiao‐Jie Yu, Jian‐Wen Wang, Long‐Di Yao, De‐Yuan Fu   +10 more
wiley   +1 more source

Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment

International Journal of Nanomedicine, 2023
Yue Zhang,1,* Xue Han,1,* Ke Wang,1 Da Liu,1 Xiaoyun Ding,2 Zhiqiang Hu,2 Jing Wang1,3 1School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 2Oncology Hospital, General Hospital of Ningxia Medical ...
Zhang Y, Han X, Wang K, Liu D, Ding X, Hu Z, Wang J   +6 more
doaj  

Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy

Advanced Science, EarlyView.
We developed an ultrasound‐controlled biomimetic nanoplatform, mRNA/V@M NPs, to co‐deliver CD74 mRNA and V‐9302 for fibrotic TNBC therapy. CD74 mRNA reprograms myCAFs into antigen‐presenting apCAF cells through the CD74‐MHC II pathway, while V‐9302 induces ICD and activates MHC I‐CD8+ T cell immunity.
Chen Ai, Weikai Sun, Yuxuan Zhao, Daqian Sun, Ting Meng, Yafei Qi, Fengyang Jiang, Jintang Sun, Zhiliang Gao, Dexin Yu   +9 more
wiley   +1 more source

Regulatory Effect of miR497-5p–CCNE1 Axis in Triple-Negative Breast Cancer Cells and Its Predictive Value for Early Diagnosis

Cancer Management and Research, 2021
Wei-Wei Liu, Wei-Dong Li, Yan-Ju Zhang, Man-Li Zhang Breast Center, Cangzhou People’s Hospital, Cangzhou 061000, Hebei Province, People’s Republic of ChinaCorrespondence: Man-Li ZhangBreast Center, Cangzhou People’s Hospital ...
Liu WW, Li WD, Zhang YJ, Zhang ML
doaj  

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

Advanced Science, EarlyView.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong, Boyang Li, Jiahui Xu, Ruonan Lin, Jinghao Pan, Chenlu Fang, Boxiang Zhang, Lucy Yue Lau, Richard J. Aldridge, Elizabeth A. Whitmore, Yi Chen   +10 more
wiley   +1 more source

A Single‐Amino‐Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome‐Targeted Degradation of Membrane Proteins

Advanced Science, EarlyView.
LA‐LYTAC repurposes the cancer‐enriched amino acid transporter LAT1 as a lysosomal trafficking receptor for targeted membrane‐protein degradation. A single phenylalanine‐derived ligand, modularly linked to antibodies or small‐molecule binders, recruits PD‐L1, EGFR, or integrins to LAT1, triggering transporter‐mediated internalization, lysosomal ...
Liquan Zhu, Ke Liu, Haotian Liu, Chaoqi He, Xiaozhen Liu, Xin Zeng, Misha Mao, Yuxiao Mu, Ying Li, Qinghui Zheng, Hongchao Tang, Da Qian, Xuli Meng   +12 more
wiley   +1 more source

Intratumoral Hypoxia Triggers Mitochondrial BHLHE40 ROS Sensing Pathway to Promote Radioresistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Hypoxia triggers a dual mechanism for BHLHE40 upregulation: reactive oxygen species (ROS)‐dependent post‐translational modification and hypoxia‐inducible factor (HIF)‐dependent transcriptional activation. Under hypoxic conditions, mitochondrial BHLHE40 accumulates and senses ROS via cysteine thiol oxidation and disulfide‐linked homodimer formation ...
Jia Liu, Ziliang Nie, Xi Chen, Guangyu Ji, Yajing Zhang, Zhiqun Zhao, Yuhong Zhang, Xinlong Du, Zhenzhen Zhou, Jiayi Li, Yaozong Yang, Fengqi Sun, Zhibo Yan, Haiquan Lu   +13 more
wiley   +1 more source

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Breast Cancer: Targets and Therapy, 2023
Rayan Dakroub,1,2 Solène Huard,1 Yara Hajj-Younes,1 Samyuktha Suresh,1 Bassam Badran,2 Hussein Fayyad-Kazan,2 Thierry Dubois1 1Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, Paris, 75005, France ...
Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T   +6 more
doaj  

Lanthanum Carbonate Nanosheets Based Colloidal Hydrogel for Modulating Innate & Adaptive Tumor Immunotherapy by Augmented Cellular Pyroptosis

Advanced Science, EarlyView.
The Gela/decitabine/La2(CO3)3 colloidal (GDLC) hydrogel developed here could reverse the epigenetic silencing of the GSDME gene by the synergistic interaction between DAC and La3+, while concurrently activating caspase‐3, thus facilitating pyroptosis induction under the tumor microenvironment.
Yang Hong, Haitao Wu, Weitao Wang, Xuan Zhang, Qian Chen, Yaoyu Hu, Zhengbao Zha   +6 more
wiley   +1 more source

PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway

Cell Death & Disease
AbstractEpidermal growth factor receptor (EGFR)-targeted drugs (erlotinib, etc.) are used to treat multiple types of tumours. EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients. However, only a small proportion of TNBC patients benefit from EGFR-targeted drugs in clinical trials, and the resistance mechanism is unclear. Here,
Yuanzhen Ma, Zhiyu Fang, Hongning Zhang, Yijun Qi, Yuke Mao, Junfang Zheng   +5 more
openaire   +3 more sources